SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

GUIDOBONI, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 484
AS - Asia 263
EU - Europa 119
SA - Sud America 1
Totale 867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 482
CN - Cina 114
SG - Singapore 103
IT - Italia 50
ID - Indonesia 38
UA - Ucraina 25
DE - Germania 12
GB - Regno Unito 12
FR - Francia 7
FI - Finlandia 6
TR - Turchia 6
SE - Svezia 4
CA - Canada 2
IN - India 2
BE - Belgio 1
BR - Brasile 1
NL - Olanda 1
RS - Serbia 1
Totale 867
Salva come PNG Salva come JPEG
Città #
Santa Clara 160
Singapore 84
Jakarta 38
Woodbridge 37
Fairfield 36
Houston 33
Jacksonville 26
Ashburn 16
Dearborn 16
Shanghai 13
Seattle 11
Cambridge 10
Chandler 10
Ferrara 10
Wilmington 9
Los Angeles 8
Milan 8
Nanjing 6
Boardman 5
Bologna 5
Izmir 5
Princeton 5
San Diego 5
Ann Arbor 4
Forlì 4
Nanchang 4
Beijing 3
London 3
Brescia 2
Brookline 2
Clifton 2
Ferrara di Monte Baldo 2
Frankfurt am Main 2
Guangzhou 2
Hebei 2
Lappeenranta 2
Monza 2
Nervesa della Battaglia 2
New York 2
Shenyang 2
Amsterdam 1
Belgrade 1
Bremen 1
Brussels 1
Chiswick 1
Crevalcore 1
Fuzhou 1
Hefei 1
Kunming 1
Ningbo 1
Ottawa 1
Rome 1
Sala Baganza 1
San Francisco 1
San Mateo 1
Springfield 1
São Paulo 1
Taiyuan 1
Tappahannock 1
Tianjin 1
Toronto 1
Xuzhou 1
Zhengzhou 1
Totale 621
Salva come PNG Salva come JPEG
Nome #
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis 116
The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up 88
Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients 70
Prognostic value of microsatellite instability and intratumor activated cytotoxic lymphocytes in colon cancer 68
Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. 57
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 20
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study 18
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 16
ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy 15
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis 15
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 15
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial 14
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study 13
First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted Therapy study) 13
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: A multicenter prospective trial 13
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma 13
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer 13
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 13
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data 12
Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis 12
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 12
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 12
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience 12
First-line, Fixed-Duration Nivolumab plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 11
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 11
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) 10
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 10
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 9
Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications 9
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 9
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 9
Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions 8
Dabrafenib-trametinib combination in 'field-practice': an Italian experience 8
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 8
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 8
Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10 : 917-923, 2001 8
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). 8
Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas - Differences between high-grade and low-grade cases 8
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 8
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 7
Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome 7
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 7
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 7
Chlamydia infection and lymphomas: Association beyond ocular adnexal lymphomas highlighted by multiple detection methods 7
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 7
Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib 6
IDIOTYPIC VACCIN 6
Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis 6
Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma 5
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma 5
High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance 5
Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes 5
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study 5
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 5
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response 5
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile 5
Melanoma vaccines in development 4
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 4
Latent membrane protein 1 deletion mutants accumulate in Reed-Sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma 4
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 4
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study 4
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability 4
Retinoic acid stabilizes p27(Kip1) in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45(Skp2) and Cks1 proteins 4
Epigenetic remodelling of DNA in cancer 4
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 4
Ipilimumab in advanced melanoma: reports of long-lasting responses 4
Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone 4
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia 4
IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas 4
MicroRNAs and dendritic cell-based vaccination in melanoma patients 4
Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes 4
Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study 4
Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type 4
Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: Pathogenic role and therapeutic perspectives 4
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas 4
Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies. 4
Totale 972
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 75
Totale 10.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202056 0 0 0 0 0 14 12 9 6 11 2 2
2020/202153 7 5 2 6 0 7 0 8 0 7 9 2
2021/202257 4 4 1 2 1 2 1 9 3 4 3 23
2022/202351 6 4 1 4 9 4 1 3 8 1 8 2
2023/2024197 3 6 3 2 0 50 0 51 0 4 19 59
2024/2025408 38 105 69 7 189 0 0 0 0 0 0 0
Totale 972